What is the efficacy of preexposure prophylaxis (PrEP) in the prevention of HIV infection?

Updated: Dec 02, 2019
  • Author: Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

Daily oral PrEP with the fixed-dose combination of tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg (Truvada) has been shown to be safe and effective in reducing the risk of sexual HIV acquisition in adults, adolescents, and discordant couples. In addition, daily administration of emtricitabine 200 mg plus tenofovir alafenamide (AF) 25 mg (Descovy) is approved in at-risk adults and adolescents for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. [149] Daily emtricitabine/tenofovir is one prevention option that is part of the general guidelines for HIV prevention. For more information, see Preexposure HIV Prophylaxis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!